ArticleClinical kidney journal2025
Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05348733 (FINE-REAL), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
FINE-REAL: A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting
Who cites it
4 citing papers in PubMed.
- Hyperkalemia risk with finerenone in diabetic kidney disease: a real-world analysis from the FINE-TURK cohort.Clinical kidney journal · 2026Article
- Hyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study.Journal of clinical medicine · 2026Article
- Finerenone Beyond Diabetic Kidney Disease: Emerging Evidence and Potential Systemic Implications.Journal of clinical medicine · 2026Review
- On interpreting renal safety signals with finerenone in FAERS.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Finerenone improves cardiovascular and renal outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), but real-world data are limited. The FINE-REAL study (NCT05348733) is examining the use of finerenone (10 or 20 mg) in participants with CKD and T2D in routine clinical practice. Methods: FINE-REAL is an ongoing global, prospective, single-arm, non-interventional study. This preplanned interim analysis was conducted 2 years after the first participant first visit. Assessments included demographics, concomitant medications and safety. Results: Data were available for 1916 participants with a median age of 68 years [interquartile range (IQR) 59-74], 65% male, with a median follow-up of 260 days (IQR 139-357). The baseline mean estimated glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration equation) was 54 ml/min/1.73 m Conclusions: In this real-world population, most participants initiated finerenone at 10 mg and remained on that dose. Finerenone was well tolerated and safety was consistent with the known profile of the drug. This interim analysis and future data from FINE-REAL will help to guide decision-making regarding the use of finerenone in participants with CKD and T2D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.